

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**DISCLOSEABLE AND CONNECTED TRANSACTION**

**UPDATE ON THE PROPOSED ACQUISITION**

References are made to the announcements issued by Sisram Medical Ltd (the “**Company**”) on 22 April and 30 June 2021 as well as the circular dispatched to the shareholders of the Company on 25 May 2021 (the “**Circular**”) in relation to the proposed acquisition of the entire issued share capital of Shanghai Foshion Medical System Co., Ltd.. Unless otherwise defined in this announcement, terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company would like to update that, all conditions to the Proposed Acquisition have been satisfied and completion of the Proposed Acquisition has occurred on July 13, 2021. Upon completion of the Proposed Acquisition, Shanghai Foshion Medical System Co., Ltd. became a wholly-owned subsidiary of the Company.

On behalf of the Board  
**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
**Yi LIU**  
*Chairman*

Hong Kong, July 13, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.*

\* for identification purpose only